Get started
HEMOSTEMIX INC
Long

Hemostemix $HEM has an agreement with Aspire Health Science.

By InvestorRelations-1

Hemostemix (TSXV: HEM) primarily deals with developing and commercializing innovative blood-derived stem cell therapies. Is now entered into an agreement with Aspire and has agreed to settle the dispute of data stealth and intellectual property infringement regarding ACP-01.
Fundamental AnalysisstocktradingtradingsignalsTrend Analysis
InvestorRelations-1
Also on:

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.